Protara Therapeutics (STU:1KPA) EV-to-Revenue : (As of May. 22, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Protara Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Protara Therapeutics's enterprise value is €9.51 Mil. Protara Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00 Mil. Therefore, Protara Therapeutics's EV-to-Revenue for today is .

The historical rank and industry rank for Protara Therapeutics's EV-to-Revenue or its related term are showing as below:

STU:1KPA's EV-to-Revenue is not ranked ^*
in the Biotechnology industry.
Industry Median: 8.215
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-22), Protara Therapeutics's stock price is €2.74. Protara Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00. Therefore, Protara Therapeutics's PS Ratio for today is .

Protara Therapeutics EV-to-Revenue Historical Data

The historical data trend for Protara Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protara Therapeutics EV-to-Revenue Chart

Protara Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

Protara Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Protara Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, Protara Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Protara Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protara Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Protara Therapeutics's EV-to-Revenue falls into.

Protara Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Protara Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	9.514	/	0
	=

Protara Therapeutics's current Enterprise Value is €9.51 Mil.
Protara Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Protara Therapeutics (STU:1KPA) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Protara Therapeutics's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	2.74	/	0
	=

Protara Therapeutics's share price for today is €2.74.
Protara Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00.

Protara Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Protara Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Protara Therapeutics (STU:1KPA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protara Therapeutics Inc (STU:1KPA) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

TARA:USA 1KPA:Germany

Address

345 Park Avenue South, 3rd Floor, New York, NY, USA, 10010

Website

http://www.protaratx.com

Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).

Protara Therapeutics (STU:1KPA) Headlines

No Headlines